Cost-effectiveness of the MitraClip device in secondary mitral regurgitation: comment upon the article by Estler et al.

[1]  S. Stock,et al.  Cost-effectiveness of the MitraClip device in German heart failure patients with secondary mitral regurgitation , 2022, The European Journal of Health Economics.

[2]  M. Mack,et al.  Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation , 2022, Heart.

[3]  M. Mack,et al.  3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. , 2021, Journal of the American College of Cardiology.

[4]  Immature survival data for cancer drugs impacts NICE decisions , 2021, PharmacoEconomics & Outcomes News.

[5]  M. Metra,et al.  COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation. , 2020, JACC. Cardiovascular interventions.

[6]  L. Frankenstein,et al.  An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK , 2020, Journal of medical economics.

[7]  M. Mack,et al.  Cost-Effectiveness of Transcatheter Mitral Valve Repair versus Medical Therapy in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial. , 2019, Circulation.

[8]  B. Bouma,et al.  Comparison of Outcome After Percutaneous Mitral Valve Repair With the MitraClip in Patients With Versus Without Atrial Fibrillation. , 2017, The American journal of cardiology.

[9]  P. Voisine,et al.  Transcatheter Mitral-Valve Repair in Patients with Heart Failure. , 2019, The New England journal of medicine.